Prednisone

• 

  Subject Areas on Research

  • "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. 
  • 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 
  • A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. 
  • A Woman With a Spot in Her Vision. 
  • A childlike presentation? 
  • A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. 
  • A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis. 
  • A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. 
  • A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. 
  • A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly. 
  • A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. 
  • A novel approach to the treatment of chronic allograft nephropathy. 
  • A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. 
  • A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. 
  • A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. 
  • A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. 
  • A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. 
  • A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. 
  • A woman with too much facial hair. Evaluating the possibility of attenuated 21-hydroxylase deficiency in hirsutism. 
  • Abiraterone in metastatic prostate cancer without previous chemotherapy. 
  • Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. 
  • Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. 
  • Advanced prostatic carcinoma: pulmonary manifestations. 
  • Affective psychoses following renal transplant. 
  • Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience. 
  • Alendronate tracheobronchitis. 
  • Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. 
  • Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. 
  • Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. 
  • An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. 
  • An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. 
  • Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. 
  • Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. 
  • Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model. 
  • Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. 
  • Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. 
  • Basal and stimulated serum growth hormone concentrations in inflammatory bowel disease. 
  • Bell's palsy. Ensuring the best possible outcome. 
  • Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). 
  • Bilateral Retinal Detachments Presenting With Acute Angle Closure. 
  • Bilateral episcleritis as a manifestation of cutaneous leukocytoclastic vasculitis. 
  • Bilateral panocular involvement with mantle-cell lymphoma. 
  • Bone density loss during treatment of chronic GVHD. 
  • Bronchiolitis by Any Other Name: Describing Bronchiolar Disorders from Inhalational Exposures. 
  • CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. 
  • CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. 
  • CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. 
  • Case report. Steroid exophthalmos. 
  • Chronic brucellosis--clinical response to reduction of suppressor T lymphocytes by cyclophosphamide/prednisone. 
  • Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. 
  • Chronic lymphocytic leukemia. 
  • Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. 
  • Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. 
  • Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. 
  • Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 
  • Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. 
  • Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. 
  • Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. 
  • Cogan's syndrome and development of ANCA-associated renal vasculitis after lengthy disease remission. 
  • Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. 
  • Combination chemotherapy for primary amyloidosis reconsidered. 
  • Combination chemotherapy in histiocytosis X. 
  • Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. 
  • Combination chemotherapy with vincristine, cyclophosphamide, and prednisone producing long-term remission of a transplanted canine lymphoma. 
  • Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. 
  • Combined medical and surgical therapy for complicated cases of peripheral uveitis. 
  • Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas. 
  • Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. 
  • Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. 
  • Comparison of prednisolone, vincristine, methotrexate, and 6-mercaptopurine vs. vincristine and prednisone induction therapy in childhood acute leukemia. 
  • Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. 
  • Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. 
  • Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. 
  • Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. 
  • Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. 
  • Coronary artery thickening with mucosal lesions in Henoch-Schönlein purpura. 
  • Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. 
  • Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab. 
  • Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. 
  • Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. 
  • Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. 
  • Cutaneous clopidogrel hypersensitivity: give steroids and do not stop the clopidogrel. 
  • Cutaneous polyarteritis nodosa. Report of a case associated with Crohn's disease. 
  • Cyclophosphamide therapy of peripheral uveitis. 
  • Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. 
  • Cyclophosphamide-asparaginase- vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia. 
  • Cyclosporin A therapy for Wegener's granulomatosis. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 
  • Cytogenetic studies and their clinical correlates in adults with acute leukemia. 
  • Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia. 
  • Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. 
  • Design, methods, and conduct of the Optic Neuritis Treatment Trial. 
  • Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. 
  • Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. 
  • Diagnosis and management of Baylisascaris procyonis infection in an infant with nonfatal meningoencephalitis. 
  • Diagnostic and Therapeutic Challenges. 
  • Diarrhea in a Patient With Combined Kidney-Pancreas Transplant. 
  • Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study. 
  • Digitalgia paresthetica with digital neuropathy in rheumatoid arthritis. 
  • Dissimilar courses of twins with leukemia. 
  • Distinct, bilateral epithelioid hemangioma of the orbit. 
  • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. 
  • Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. 
  • Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. 
  • Drug rash with eosinophilia and systemic symptoms (DRESS syndrome). 
  • Drug-induced granulomatous interstitial nephritis in a pediatric patient. 
  • Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. 
  • Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. 
  • Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. 
  • Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. 
  • Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry. 
  • Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. 
  • Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis. 
  • Effect of two prednisone exposures on mood and declarative memory. 
  • Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. 
  • Effects of short-term administration of glucocorticoids on bone metabolism in healthy elderly men. 
  • Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. 
  • Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. 
  • Endophthalmitis following Nd:YAG laser posterior capsulotomy. 
  • Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. 
  • Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. 
  • Evaluation of dose and schedule of L-asparaginase in multidrug therapy of childhood leukemia. 
  • Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. 
  • Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. 
  • Exudative retinal detachment and retinitis associated with acquired syphilitic uveitis. 
  • Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. 
  • Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study. 
  • Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. 
  • Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. 
  • Hepatic focal nodular hyperplasia in infant antenatally exposed to steroids. 
  • Hexamethylmelamine and prednisone in the treatment of refractory multiple myeloma. 
  • High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. 
  • High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. 
  • High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. 
  • Hodgkin's disease presenting as myelofibrosis. 
  • Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by glucocorticosteroid administration. 
  • Hydroxychloroquine in lupus pregnancy. 
  • Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. 
  • Hydroxychloroquine-induced hyperpigmentation: the staining pattern. 
  • Hyperlucent lung after radiation therapy. 
  • Idiopathic thrombocytopenic purpura: mother and neonate. 
  • Ileocolonic perforation. A complication following renal transplantation. 
  • Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. 
  • Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. 
  • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. 
  • Immunogenetics of consanguineous allografts in man. II. Correlation of renal allografting with HL-A genotyping. 
  • Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. 
  • Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. 
  • Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. 
  • Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy. 
  • Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. 
  • Incidence of cytomegalovirus disease in renal transplantation without antilymphocyte induction: is prophylaxis necessary? 
  • Insulin receptor of fat cells in insulin-resistant metabolic states. 
  • Islands of Inflammation: Neurosarcoidosis. 
  • Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. 
  • Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. 
  • Ketoconazole and prednisone to prevent recurrent ischemic priapism. 
  • L-N-Acetylcysteine treatment is associated with improved hearing outcome in sudden idiopathic sensorineural hearing loss. 
  • Laboratory correlates and prognostic significance of granular acute lymphoblastic leukemia in children. A Pediatric Oncology Group study. 
  • Long-term complications of bone marrow transplantation. 
  • Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. 
  • Long-term follow-up of survival in Hodgkin's lymphoma. 
  • Long-term results of reinforcement therapy in children with acute leukemia. 
  • Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. 
  • Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans. 
  • Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. 
  • Lymphoblastic lymphoma in children--a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study. 
  • Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years. 
  • MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. 
  • Management of childhood onset nephrotic syndrome. 
  • Managing older adults with CKD: individualized versus disease-based approaches. 
  • Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. 
  • Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. 
  • Methods to prevent rejection of homografts in man: a report on living related kidney donor selection by HL-A genotyping. 
  • MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. 
  • Minimal manifestation status and prednisone withdrawal in the MGTX trial. 
  • Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). 
  • Motor variant of chronic inflammatory demyelinating polyneuropathy in a child. 
  • Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. 
  • Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report. 
  • Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. 
  • Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. 
  • Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. 
  • NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. 
  • Neonatal pemphigus vulgaris in a child born to a woman in remission. 
  • Neuromuscular ultrasound findings in eosinophilic fasciitis: A case series and literature review. 
  • Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. 
  • Nocardia osteomyelitis. Case report and review of the literature. 
  • Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. 
  • Nonketotic hyperglycemia due to prednisone (NSC-10023) following ketotic hyperglycemia due to L-asparaginase (NSC-109229) plus prednisone. 
  • Ocular Surface Epithelial Atypia Mimicking Squamous Neoplasia in Association With Ulcerative Colitis. 
  • Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. 
  • Orthopedic complications of renal transplantation in children. 
  • Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. 
  • Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. 
  • POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. 
  • PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. 
  • Painful acute radiation thyroiditis induced by 131I treatment of Graves' disease. 
  • Panniculitis in juvenile dermatomyositis. 
  • Paraneoplastic pemphigus associated with non-Hodgkin lymphoma. 
  • Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. 
  • Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. 
  • Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: Daily and cumulative dose. 
  • Peripheral T-cell lymphoma with unusual clinical presentation of rhabdomyolysis. 
  • Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. 
  • Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. 
  • Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma. 
  • Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. 
  • Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. 
  • Phase II study demonstrating failure of both a five-drug continuous-therapy regimen and a two-drug pulse-therapy regimen in the treatment of metastatic neuroblastoma: Southwest Oncology Group Study 822. 
  • Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B. 
  • Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. 
  • Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. 
  • Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). 
  • Polymyositis as a manifestation of chronic graft-versus-host disease. 
  • Postoperative Venous Thromboembolism in Patients Undergoing Abdominal Surgery for IBD: A Common but Rarely Addressed Problem. 
  • Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. 
  • Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. 
  • Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. 
  • Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. 
  • Prednisone-responsive aplastic anemia associated with T-lymphocyte proliferation. 
  • Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. 
  • Presentation of multicentric Castleman's disease with sicca syndrome, cardiomyopathy, palmar and plantar rash. 
  • Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. 
  • Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. 
  • Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. 
  • Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. 
  • Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. 
  • Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. 
  • Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. 
  • Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. 
  • Pseudomonas septicemia with nodules and bullae. 
  • Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. 
  • Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis. 
  • Pyoderma gangrenosum, altered delayed hypersensitivity and polyarthritis. 
  • Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy. 
  • Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. 
  • Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. 
  • Randomized Trial of Thymectomy in Myasthenia Gravis. 
  • Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. 
  • Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. 
  • Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. 
  • Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. 
  • Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. 
  • Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. 
  • Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 
  • Recurrence of cardiac sarcoidosis in a heart transplant recipient. 
  • Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation. 
  • Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. 
  • Remission induction with L-asparaginase, vincristine, and prednisone in children with acute nonlymphoblastic leukemia. 
  • Removal of intravitreous cysticerci from the surface of the optic nervehead. A pars plana approach. 
  • Renal agenesis after first trimester exposure to chlorambucil. 
  • Renal transplantation at the University of Wisconsin in the cyclosporine era. 
  • Renal transplantation between HL-A identical donor-recipient pairs. Functional and morphological evaluation. 
  • Renal transplantation between histocompatible donor-recipient pairs. 
  • Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome. 
  • Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium. 
  • Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. 
  • Retroperitoneal fibrosis following treatment for Hodgkin's disease. 
  • Retroperitoneal fibrosis in children. 
  • Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. 
  • Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. 
  • Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis. 
  • Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. 
  • Role of gluten, prednisone, and azathioprine in non-responsive coeliac disease. 
  • Salmon calcitonin reduces vertebral bone loss in glucocorticoid-treated beagles. 
  • Selection of donors for kidney transplantation. 
  • Septic arthritis due to Mycoplasma hominis. 
  • Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy. 
  • Severe insulin resistance in a patient with type 1 diabetes and stiff-man syndrome treated with insulin lispro. 
  • Should abdominal cluster transplantation be abandoned? 
  • Single fiber electromyography in myasthenia gravis during pregnancy. 
  • Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • Small lymphocytic lymphoma presenting as a paraneoplastic syndrome with acute central nervous system demyelination. 
  • Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment. 
  • Steroid premedication before i.v. contrast-enhanced CT resulting in resolution of lymphadenopathy. 
  • Steroid-responsive encephalopathy associated with Hashimoto's thyroiditis in an adolescent with chronic hallucinations and depression: case report and review. 
  • Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. 
  • Stromal gene signatures in large-B-cell lymphomas. 
  • Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. 
  • Successful treatment of sudden hearing loss in Cogan's syndrome with corticosteroids. 
  • Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. 
  • Susac syndrome with transient inverted vision. 
  • Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. 
  • Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone. 
  • Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. 
  • Ten years' experience with LSA2-L2 therapy for childhood advanced lymphoblastic lymphoma. 
  • Thalidomide as salvage therapy for chronic graft-versus-host disease. 
  • The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes. 
  • The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study. 
  • The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. 
  • The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. 
  • The effect of total lymphoid irradiation and low-dose steroids on T lymphocyte populations in multiple sclerosis: correlation with clinical and MRI status. 
  • The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. 
  • The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. 
  • The importance of class I and class II HLA in cadaveric renal transplantation. 
  • The importance of studying history: lessons learnt from a trial of tacrolimus in myasthenia gravis. 
  • The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma. 
  • The radiographic diagnosis and treatment of paraneoplastic central nervous system disease. 
  • The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. 
  • The renal failure that vanished. 
  • Therapeutic vaccines for aggressive B-cell lymphoma. 
  • Therapy of myeloma. 
  • Thrombotic thrombocytopenic purpura occurring despite absence of the spleen: report of case. 
  • Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. 
  • Treatment modalities in Guillain-Barré syndrome. 
  • Treatment of Mycobacterium haemophilum infection with an antibiotic regimen including clarithromycin. 
  • Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone. 
  • Treatment of red cell aplasia with antithymocyte globulin: repeated inductions of complete remissions in two patients. 
  • Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. 
  • Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. 
  • Troglitazone-associated hepatotoxicity treated successfully with steroids. 
  • Update in the management of patients with hormone-refractory prostate cancer. 
  • Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. 
  • Use of OKT3 in kidney, pancreas, and liver transplantation. 
  • Use of azathioprine in nine children with Crohn's disease. 
  • Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. 
  • Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. 
  • Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. 
  • Vincristine therapy for severe platelet alloimmunization. 
  • Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group. 
  • Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. 
  • What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? 
• 

  Keywords of People

  • Allen, Nancy Bates, Professor Emeritus of Medicine, Medicine, Rheumatology and Immunology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Schanberg, Laura Eve, Professor of Pediatrics, Pediatrics, Rheumatology